Everything below concerns Reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
1993/2854) Birmingham City Council (Grand Union Canal Bridge) Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/2855) Mid Essex Community and Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2856) Wigan and Leigh Health Services National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2857) Public Airport Companies (Capital Finance) (Fourth Amendment) Order 1993 (S.I. 1993/2875) Conservation of Seals (England) Order 1993 (S.I. 1993/2876) Motor Vehicles Tyres (Safety) (Amendment) Regulations 1993 (S.I. 1993/2877) Local Government Reorganisation (Capital Money) (Greater London) (Amendment) Order 1993 (S.I. 1993/2878) Redbridge and Waltham Forest (London Borough Boundaries) Order 1993 (S.I. 1993/2881) Local Government (Compensation for Premature Retirement) (Amendment) Regulations 1993 (S.I. 1993/2890) Local Government Act 1988 (Defined Activities) (Exemption) (Wales) (No. 2) Order 1993 (S.I. 1993/2894) Protection of Wrecks (Designation No. 3) Order 1993 (S.I. 1993/2895) Community Health Sheffield National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2896) Public Telecommunication System Designation (Scottish Power Telecommunications Limited) Order 1993 (S.I. 1993/2897) Public Telecommunication System Designation (Torch Communications Limited) Order 1993 (S.I. 1993/2898) Public Telecommunication System Designation (MFS Communications Limited) Order 1993 (S.I. 1993/2899)
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis). It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection and is known by patients as "fire in the veins". Melarsoprol has a high number of side effects. Common side effects include brain dysfunction, numbness, rashes, and kidney and liver problems. About 1–5% of people die during treatment, although this is tolerated due to sleeping sickness itself having a practically 100% mortality rate when untreated. In those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cell breakdown may occur. It has not been studied in pregnancy. While its mechanism of action is not fully understood, its covalent binding to trypanothione to form the toxic Mel T complex is thought to play a large role. Melarsoprol has been used medically since 1949. It is on the World Health Organization's List of Essential Medicines. In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization. It is not commercially available in Canada or the United States. In the United States, it may be obtained from the Centers for Disease Control and Prevention, while in Canada it is available from Health Canada.
In molecular biology, Proteinase K (EC 3.4.21.64, protease K, endopeptidase K, Tritirachium alkaline proteinase, Tritirachium album serine proteinase, Tritirachium album proteinase K) is a broad-spectrum serine protease. The enzyme was discovered in 1974 in extracts of the fungus Parengyodontium album (formerly Engyodontium album or Tritirachium album). Proteinase K is able to digest hair (keratin), hence, the name "Proteinase K". The predominant site of cleavage is the peptide bond adjacent to the carboxyl group of aliphatic and aromatic amino acids with blocked alpha amino groups. It is commonly used for its broad specificity. This enzyme belongs to Peptidase family S8 (subtilisin). The molecular weight of Proteinase K is 28,900 daltons (28.9 kDa).
Sources: en.wikipedia.org
Not only did the people of ancient Mexico use the same methods of production as the Phoenicians, they also valued murex-dyed cloth above all others, as it appeared in codices as the attire of nobility. "Nuttall noted that the Mexican murex-dyed cloth bore a "disagreeable ... strong fishy smell, which appears to be as lasting as the colour itself." Likewise, the ancient Egyptian Papyrus of Anastasi laments: "The hands of the dyer reek like rotting fish". So pervasive was this stench that the Talmud specifically granted women the right to divorce any husband who became a dyer after marriage. In 2021, archaeologists found surviving wool fibers dyed with royal purple in the Timna Valley in Israel. The find, which was dated to c. 1000 BC, constituted the first direct evidence of fabric dyed with the pigment from antiquity.
MLSE and NBA had applied to register the Raptor's logo Raptors, a basketball with three diagonal claw gashes, for various goods and services. The Trademark Trial and Appeal Board dismissed Monster's claim. In March 2016, Monster filed a lawsuit to revoke the company trademark of Thunder Beast LLC of Washington, D.C., a small root beer brewery, insisting the use of "beast" in the company name encroached on Monster's trademark slogan, "Unleash the Beast". The owner of Thunder Beast, Stephen Norberg, was fighting Monster's lawsuit as of 2019. In August 2018, Monsta Pizza of Wendover in Buckinghamshire, United Kingdom, fought a claim brought by Monster Energy in the Intellectual Property Office. The claim was that the pizza firm could be mistaken for Monster Energy, leaving customers confused. The pizza firm won a landmark ruling against Monster Energy, when the court decided there would be no case of misrepresentation. In fact, Monster Energy loses many of their lawsuits; however, as with other cases of "trademark bullying", the main goal of the lawsuit seems to be bankrupting the opposition at which they are quite successful. Also in 2018, Monster Energy brought a lawsuit against Vital Pharmaceuticals Inc. (VPX), then producer of Bang Energy, a competitor of Monster Energy. The lawsuit alleged false advertising as well as theft of trade secrets. The matter concluded with a jury verdict in favor of Monster Energy.
==== Lay Low ==== In January 2015, Doillon started recording and co-producing, alongside Timber Timbre frontman Taylor Kirk, her second album in Canada. She recorded in the Montreal mythical studio Hotel2Tango, over a period of a month, with fellow band members of Timber Timbre. She completed the recording between Studio la Seine in Paris and RAK Studios in London. Lay Low was mixed by Nick Launey and Adam Greenspan in Los Angeles in April. The album came out on 9 October, preceded by the first single "Where to Start", which was featured in Jean-Marc Vallée's' movie Demolition (starring Naomi Watts and Jake Gyllenhaal) soundtrack. Doillon was nominated for best rock album of the year at Les Victoires de la musique. The album received critical acclaim in France, Belgium, England, Canada and the US and was released through Verve in the US and decca in the UK. The front cover for the album is a selfie shot by Doillon in bed, and inner pictures were shot during the recording in Canada by French photographer Zelie Noreda. In 2016, Doillon started a world tour, performing in the US, Canada, Japan, Australia, Korea, Germany, Poland, England and France. She performed on Jools Holland, alongside Iggy Pop and Graham Nash. As a final touch to her world tour, she performed two sold out concerts in La Flèche D'or, named Kitchen Acoustic and Lou Doillon and Friends (performed with fellow musicians Woodkid and Keren Ann).
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.